Takuro Shirasu

Takuro Shirasu

Auto-generated profile, based on publicly available information

Takuro Shirasu

Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
TSTakuro Shirasu
Takuro Shirasu
HTHisato Takagi
Hisato Takagi
AGAlexander Gregg
Alexander Gregg
TKToshiki Kuno
Toshiki Kuno
JYJun Yasuhara
Jun Yasuhara
WCW. Darrin Clouse
W. Darrin Clouse

1 January 2023 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
JYJun Yasuhara
Jun Yasuhara
KMKaihei Masuda
Kaihei Masuda
TATadao Aikawa
Tadao Aikawa
TSTakuro Shirasu
Takuro Shirasu
HTHisato Takagi
Hisato Takagi
TKToshiki Kuno
Toshiki Kuno
The COVID-19 global pandemic began in December 2019.1 The introduction of the messenger RNA (mRNA) vaccine against SARS-CoV-2 has resulted in a significant decline in COVID-19–related morbidity and mortality all over the world.2-4 COVID-19 mRNA vaccines are the current standard approach to contain the pandemic and the Emergency Use Authorizations for these vaccines were recently extended to children aged 6 months and older in the US. Since the emergency use was authorized, the association of the mRNA-based COVID-19 vaccine with myopericarditis, which is a rare but serious adverse event, has been reported.5,6 Cases of myopericarditis following COVID-19 mRNA vaccination have been reported worldwide, especially in adolescents and young adults. In addition, in June 2021, the Centers for Disease Control and Prevention (CDC) observed a rate of postvaccine myopericarditis that was higher in young males after the second mRNA vaccine doses.7 Previous studies reported largely favorable outcomes in adults with myocarditis following COVID-19 mRNA vaccination, demonstrating resolution of clinical symptoms, preservation of cardiac function, and no complications.8-11 However, data on the clinical features and outcomes of myopericarditis after COVID-19 vaccination in adolescents and young adults are scarce compared with adults and often consist of small case series. Most large-scale studies on COVID-19 vaccine–associated myopericarditis among adolescents and young adults are derived from national population-based studies that contain homogeneous populations or from surveillance networks that rely on passive reporting. In this study, we conducted a systematic review and meta-analysis to investigate the clinical spectrum and outcomes of COVID-19 vaccine–associated myopericarditis in adolescents and young adults from an international population.

7 December 2023 in Journal of Vascular Surgery
Verified
Journal Article
Open access
TSTakuro Shirasu
Takuro Shirasu
AAAtsushi Akai
Atsushi Akai
MMManabu Motoki
Manabu Motoki
MKMasaaki Kato
Masaaki Kato
To analyze the effects of total side branch embolization at endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) on the incidences of persistent type 2 endoleak (pT2EL), changes in sac diameter, and re-intervention. Between 2013 and 2021, all patients who underwent primary EVAR with a few exceptions were included. Side branch embolization was considered during EVAR for inferior mesenteric artery (IMA) or IMA plus lumbar artery (LA) when feasible for contrast agent use. Outcomes measured were pT2EL, sac diameters, re-intervention, ruptures, and aneurysm related mortality. Radiation exposure and safety outcomes were also reported. Among 732 patients undergoing EVAR, 616 patients (84.2%) were included, of whom 223 patients (36.2%) did not undergo side branch embolization (NO-E), while 228 patients (37.0%) underwent IMA only (IMA-E) and 165 patients (26.8%) IMA+LA including median sacral artery (IMA+LA-E). The technical success rate of IMA and LA embolization was 97.0% and 74.7%, respectively. Crude incidences of pT2EL was significantly different from 6 months through 3 years (NO-E, 27.8%; IMA-E, 31.7%; IMA+LA-E, 9.4% at 3 years; p = .007). In the multivariate analysis adjusted for background differences, the incidences of pT2EL was significantly higher in the NO-E (odds ratio [OR], 3.21; 95% confidence intervals [CIs], 1.08-9.57; p = .004) and IMA-E (OR, 4.86; 95% CIs 1.68-14.11; p = .004) compared to the IMA+LA-E group. Similarly, any re-intervention until 3 years was significantly frequent in the NO-E (OR, 5.26; 95% CIs 1.76-15.70; p = .003) and IMA-E group (OR 4.19; 95% CIs 1.38-12.67; p = .01). Surgical conversion and secondary rupture were seen only in 1 patient without any aneurysm related mortality. % sac shrinkage from the baseline was significantly promoted in the IMA+LA group (NO-E, 12.1% ± 16.6%; IMA-E, 11.4% ± 16.7%; IMA+LA-E, 18.0% ± 18.8%; p = .047). Fluoroscopy time was significantly longer in the IMA+LA-E group (NO-E, 60.2 ± 47.4 min; IMA-E, 59.3 ± 39.5 min; IMA+LA-E, 75.5 ± 42.8 min, p < .0001), and so do the dose-area product (NO-E, 424.6 ± 333.4 Gycm2; IMA-E, 477.7 ± 342.4 Gycm2; IMA+LA-E, 631.8 ± 449.1 Gycm2, p < .0001). No embolization-related complications or radiation-related adverse events were recorded. Preemptive embolization of IMA, LAs and median sacral artery at the time of EVAR reduced the incidences of pT2EL and any re-intervention and promoted sac shrinkage during the follow-up period of 3 years.

1 August 2023 in Bioactive Materials
Verified
Journal Article
Open access
NYNisakorn Yodsanit
Nisakorn Yodsanit
TSTakuro Shirasu
Takuro Shirasu
YHYitao Huang
Yitao Huang
LYLi Yin
Li Yin
ZIZain Husain Islam
Zain Husain Islam
BWBowen Wang
Bowen Wang
Abdominal aortic aneurysm (AAA) is a progressive aortic dilatation, causing ∼80% mortality upon rupture. Currently, there is no approved drug therapy for AAA. Surgical repairs are invasive and risky and thus not recommended to patients with small AAAs which, however, account for ∼90% of the newly diagnosed cases. It is therefore a compelling unmet clinical need to discover effective non-invasive strategies to prevent or slow down AAA progression. We contend that the first AAA drug therapy will only arise through discoveries of both effective drug targets and innovative delivery methods. There is substantial evidence that degenerative smooth muscle cells (SMCs) orchestrate AAA pathogenesis and progression. In this study, we made an exciting finding that PERK, the endoplasmic reticulum (ER) stress Protein Kinase R-like ER Kinase, is a potent driver of SMC degeneration and hence a potential therapeutic target. Indeed, local knockdown of PERK in elastase-challenged aorta significantly attenuated AAA lesions in vivo. In parallel, we also conceived a biomimetic nanocluster (NC) design uniquely tailored to AAA-targeting drug delivery. This NC demonstrated excellent AAA homing via a platelet-derived biomembrane coating; and when loaded with a selective PERK inhibitor (PERKi, GSK2656157), the NC therapy conferred remarkable benefits in both preventing aneurysm development and halting the progression of pre-existing aneurysmal lesions in two distinct rodent models of AAA. In summary, our current study not only establishes a new intervention target for mitigating SMC degeneration and aneurysmal pathogenesis, but also provides a powerful tool to facilitate the development of effective drug therapy of AAA.

28 November 2017 in BMC Surgery
Verified
Journal Article
Open access
PDF file
TTTetsuro Toriumi
Tetsuro Toriumi
TSTakuro Shirasu
Takuro Shirasu
AAAtsushi Akai
Atsushi Akai
YOYuichi Ohashi
Yuichi Ohashi
TFTakatoshi Furuya
Takatoshi Furuya
YNYukihiro Nomura
Yukihiro Nomura
It has been reported that median arcuate ligament syndrome is closely associated with gastric or pancreaticoduodenal artery aneurysms. Hemodynamic state plays an important role in the formation of the aneurysms. These aneurysms are treated with open resection or endovascular exclusion. However, whether revascularization of the celiac artery can prevent the aneurysm formation is unknown. This report indicated a possibility that prophylactic revascularization for celiac artery stenosis resulted in decreased shear stress on the collaterals, which may otherwise be susceptible to new aneurysms. This report describes a 51-year-old man who presented with epigastric pain at our hospital. According to contrast enhanced computed tomography (CT), he was diagnosed with a ruptured right gastric artery aneurysm and celiac artery stenosis caused by the median arcuate ligament (MAL). He had a vascular anomaly of the common hepatic artery arising from the superior mesenteric artery (SMA). His vital signs were stable. We informed him of the situation and he chose open surgery rather than endovascular treatment. Following, we resected the aneurysm and transected the MAL. Intraoperative angiography after transection of the MAL showed the antegrade blood flow to the splenic artery instead of the retrograde flow via the prominent collaterals. Follow-up CT confirmed narrowed collateral vessels between the SMA and the celiac artery without de-novo aneurysms. While the necessity of celiac artery release could be questioned, the present case supports the hemodynamic benefits of MAL transection in terms of de-novo aneurysm prevention.

3 January 2023 in Annals of Surgery
Verified
Journal Article
Closed access
TSTakuro Shirasu
Takuro Shirasu
HTHisato Takagi
Hisato Takagi
JYJun Yasuhara
Jun Yasuhara
TKToshiki Kuno
Toshiki Kuno
KKK. Craig Kent
K. Craig Kent
WCW. Darrin Clouse
W. Darrin Clouse
Objective: The aim was to analyze the risk of progression to chronic limb-threatening ischemia (CLTI), amputation and subsequent interventions after revascularization versus noninvasive therapy in patients with intermittent claudication (IC). Background: Conflicting evidence exists regarding adverse limb outcomes after each treatment strategy. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. MEDLINE, Web of Science, and Google Scholar were searched aided by a health sciences librarian through August 16, 2022. Randomized control trials (RCTs) comparing invasive (endovascular or surgical revascularization) and noninvasive treatment (exercise and/or medical treatment) were included. PROSPERO registration was completed (CRD42022352831). Results: A total of 9 RCTs comprising 1477 patients (invasive, 765 patients; noninvasive, 712 patients) were eligible. During a mean of 3.6-year follow-up, progression to CLTI after invasive [5 (2–8) per 1000 person-years] and noninvasive treatment [6 (3–10) per 1000 person-years] were not statistically different [rate ratio (RR): 0.77; 95% CI, 0.35–1.69; P=0.51, I 2=0%]. Incidence of amputation (RR: 1.69; 95% CI, 0.54–5.26; P=0.36, I 2=0%) and all-cause mortality (hazard ratio: 1.26; 95% CI, 0.91–1.74; P=0.16, I 2=0%) also did not differ between the groups. However, the invasive treatment group underwent significantly more revascularizations (RR: 4.15; 95% CI, 2.80–6.16; P<0.00001, I 2=83%). The results were not changed by fixed effect or random-effects models, nor by sensitivity analysis. Conclusions: Although there is equivalent risk of progression to CLTI, major amputation and all-cause mortality compared with noninvasive treatment, invasive treatment for patients with IC led to significantly more revascularization procedures and should be used selectively in patients with major lifestyle limitation. Guideline recommendation of noninvasive treatment for first-line IC therapy is supported.